Return to List

Study Summary
No. 2006-0707:.......Kidney......Surena Matin......Urology
.
Study Summary Title
Study Summary
Number:		2006-0707
Study Title:Development and Validation of a Kidney Cancer Questionnaire for Use in Patients with Renal Tumors Suspicious for Renal Cell Carcinoma
.
Physician New Patient Referral
Name:Surena MatinPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:UrologyReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-3250
Contact us about clinical trials
.
General Information
Disease Group:KidneySupported By:N/A
Phase of Study:N/AReturn
Visit:		Not applicable
Treatment
Agents:		QuestionnaireHome Care:Not applicable
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:		Not applicable
Description/
Intervention:		The goal of this psychosocial research study is to develop a questionnaire to
measure the quality of life in patients with renal tumors that may be RCC.
.
Study Objectives / Outcomes
The objective of this study is to develop and validate a quality of life (QOL) questionnaire for patients with tumors consistent with localized renal cell carcinoma (RCC). There are no existing QOL measures specifically for patients with localized RCC. QOL outcome measures will be correlated with renal function and specifically to creatinine clearance.
.
Study Status Information
Study Activation / Registration Date:05/11/2007
IRB Review and Approval Date:05/11/2007
Study Type:Behavioral
Recruitment Status:Terminated
Projected Accrual:N/A
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:1) Patient Inclusion - Any M. D. Anderson cancer patient with a renal tumor that would be consistent with (or suspicious for) localized renal cell carcinoma. Both treated and untreated patients are included, depending on the phase of the study. In either case, there should be no evidence of extra-renal disease or local recurrence.

2) Patient Inclusion - English speaking

3) Patient Inclusion - Able to provide informed consent

4) Clinician Inclusion - Clinician (MD, DO, or RN) with expertise in the treatment of renal cell carcinoma

5) Clinician Inclusion - English speaking
Exclusion Criteria:1) Patient Exclusion - prior non-cutaneous or non-renal cancer within 3 years. The PI may exclude patients who may be more than 3 years out from treatment of a non-cutaneous non-renal cancer if associated medical or psychosocial issues are felt to still be active and possibly interfere with current measures.

2) Patient Exclusion - Age under 18 years.

3) Clinician Exclusion - Unable to provide informed consent
.
Links
Registration Number: Not Applicable Clinical Trial
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center